Datadog Stock Gets Bullish Boost: Guggenheim Predicts 27% Growth in 2026
Guggenheim upgrades Datadog to Buy: AI boosts demand, strong moat, ~50% upside, solid growth ahead.
Already have an account? Sign in.
Guggenheim upgrades Datadog to Buy: AI boosts demand, strong moat, ~50% upside, solid growth ahead.
Guidewire beat Q3 earnings, but a weak ARR outlook worried investors, sending shares down despite strong revenue growth.
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.